FOR PATIENTS’ RIGHTS LEARN MORE DONATE NOW People who have or have had breast cancer can help find the cures, faster. Your breast cancer information is as unique as you are. When combined with other ShareForCures members, you provide scientists with a more diverse set of data to make new...
Conquer Cancer Foundation Grants and Awards Program
Australian National Breast Cancer Foundation Grants National Breast Cancer Foundation is the primary funder of Australia for all breast cancer researches. Since its conception, NBCF has funded over 370 Australian based research projects. Last year in the month of January NBCF has introduced one more...
G. Thompson (“Tom”) Hutton, the Trustee of the Geoffrey Beene Foundation and President and CEO of Geoffrey Beene, LLC, (until 2018) initiated the creation of the Center primarily for the purpose of funding new revolutionary research leading to new treatments for cancer patients and orchestrated...
Some of these measures have been shown to be reliable predictors of a drug’s clinical advantage, such as a benefit in disease-free survival (DFS) that predicts a benefit in overall survival (OS) for patients with colorectal cancer3; however, other surrogate measures have been found to be ...
M.G.V.H. reports support from the Lustgarten Foundation, the MIT Center for Precision Cancer Medicine, the Ludwig Center at MIT and NIH grants R35 CA242379 and P30 CA1405141. Author information Author notes These authors contributed equally: Adrienne Boire, Katy Burke, Thomas R. Cox, ...
Conflict of Interest Disclosures: Dr Unger reported receiving a grant from the Hope Foundation for Cancer Research related to this research. Dr Blanke reported receiving grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) related to this research. Dr LeBlanc ...
We aimed to investigate the effect of thyroid hormone administration on the risk of second primary cancer in patients who underwent thyroidectomy for differentiated thyroid cancer. Data were extracted from the medical billing data of the Health Insurance
Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein VI, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled ISAR-PLASTER phase 2 trial. JAMA Cardiol. 6, ...
Conflict of Interest Disclosures: Dr Tanner reported receiving funding from Exact Sciences, Veracyte Inc, and Integrated Diagnostics; receiving foundation grants from Veterans Affairs Health Services Research and Development, the American Cancer Society, and Chest Foundation; serving as a consultant for Int...